Alphamab Oncology
HKEX:9966

Watchlist Manager
Alphamab Oncology Logo
Alphamab Oncology
HKEX:9966
Watchlist
Price: 6.91 HKD -0.43% Market Closed
Market Cap: 6.6B HKD

Wall Street
Price Targets

Price Targets Summary
Alphamab Oncology

Wall Street analysts forecast Alphamab Oncology stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Alphamab Oncology is 4.93 HKD with a low forecast of 2.53 HKD and a high forecast of 7.35 HKD.

Lowest
Price Target
2.53 HKD
63% Downside
Average
Price Target
4.93 HKD
29% Downside
Highest
Price Target
7.35 HKD
6% Upside
Alphamab Oncology Competitors:
Price Targets
MNPR
Monopar Therapeutics Inc
40% Upside
INMB
INmune Bio Inc
205% Upside
VCYT
Veracyte Inc
38% Upside
ELUT
Elutia Inc
294% Upside
2315
Biocytogen Pharmaceuticals Beijing Co Ltd
30% Upside
6160
Beigene Ltd
8% Upside
214450
PharmaResearch Co Ltd
8% Downside
301080
Acrobiosystems Co Ltd
8% Upside

Revenue
Forecast

Revenue Estimate
Alphamab Oncology

The compound annual growth rate of Alphamab Oncology's revenue for the next 3 years is 39%.

N/A
Past Growth
39%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Alphamab Oncology

The compound annual growth rate of Alphamab Oncology's operating income for the next 3 years is 70%.

N/A
Past Growth
70%
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Net Income
Forecast

Net Income Estimate
Alphamab Oncology

The compound annual growth rate of Alphamab Oncology's net income for the next 3 years is 64%.

N/A
Past Growth
64%
Estimated Growth
Estimates Accuracy
-21%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Alphamab Oncology's stock price target?
Price Target
4.93 HKD

According to Wall Street analysts, the average 1-year price target for Alphamab Oncology is 4.93 HKD with a low forecast of 2.53 HKD and a high forecast of 7.35 HKD.

What is Alphamab Oncology's Revenue forecast?
Projected CAGR
39%

The compound annual growth rate of Alphamab Oncology's revenue for the next 3 years is 39%.

What is Alphamab Oncology's Operating Income forecast?
Projected CAGR
70%

The compound annual growth rate of Alphamab Oncology's operating income for the next 3 years is 70%.

What is Alphamab Oncology's Net Income forecast?
Projected CAGR
64%

The compound annual growth rate of Alphamab Oncology's net income for the next 3 years is 64%.

Back to Top